deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT00585507

Efficacy and Safety of 500mg of Fulvestrant

A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Sponsor: Beth Israel Deaconess Medical Center

Conditions Breast Cancer
Interventions Fulvestrant
Updated 14 times since 2017 Last updated: Jul 7, 2025 Started: Apr 30, 2004 Primary completion: Mar 15, 2026 Completion: Mar 15, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and is currently ongoing. Beth Israel Deaconess Medical Center leads this study, which shows 14 recorded versions since 2004 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Jul 2020 · 11 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Jul 2022 · 13 months · monthly snapshot~Jul 2022 – ~Apr 2024 · 21 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Aug 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Jul 2022 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Feb 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
  • Lowell General Hospital
  • Massachusetts General Hospital
  • South Shore Hospital
  • University of Colorado, Denver
  • University of Maryland Greenebaum Cancer Center
Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations